BioCentury
ARTICLE | Distillery Therapeutics

Cardiovascular

August 8, 2018 11:50 PM UTC

Mouse studies suggest inhibiting the integrin CD29 could help treat vascular leakage caused by endotoxemia associated with sepsis. In a lipopolysaccharide (LPS)-induced mouse model of endotoxemia, an anti-CD29 mAb decreased vascular leakage and increased cardiac ejection fraction compared with a control antibody. Also in the model, heterozygous knockout of CD29 decreased vascular leakage compared with normal expression. Next steps could include testing CD29 inhibitors in additional models of endotoxemia...

BCIQ Company Profiles

University of Helsinki

BCIQ Target Profiles

Integrin beta(1) (CD29)